Short-term gluCOCOrticoid in Adult STEROID-sensitive Nephrotic Syndrome: The COCO-ASTEROID Study

Inclusion Criteria: * Urine protein: creatinine ratio ≥3000mg/g (300mg/mmol) * Serum/plasma albumin level \< 30g/L * Age ≥ 16 years at the time of diagnosis * No prior therapy with steroids, immunosuppressive or cytotoxic agents for any form of renal disease (other than the 28 days of prednisolone therapy given initially as routine clinical practice) * No evidence of underlying systemic disorder or exposure to agents known to be associated with newly presenting steroid sensitive nephrotic syndrome * Informed consent * SSNS defined as Complete remission within 4 weeks of prednisone or prednisolone at standard dose Exclusion Criteria: * Secondary nephrotic syndrome * Contradictions for glucocorticoids * SRNS: Lack of complete remission within 4 weeks of therapy with daily prednisone or prednisolone at standard dose * anti-PLA2R positive * Adults with histological changes other than minimal lesion or focal segmental glomerular sclerosis (FSGS) glomerulonephritis where renal biopsy has been undertaken * Adults with a prior history of poor compliance with medical therapy Known allergy to glucocorticoid therapy * Other situations where the researcher deems it inappropriate to participate in the study